Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + temozolomide + electroacupuncture
- Development stage
- Unknown
- Lead developer
- Third Affiliated Hospital of Zhejiang Chinese Medical University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This therapeutic regimen, developed by The Third Affiliated Hospital of Zhejiang Chinese Medical University, combines the chemotherapeutic agents albumin-bound paclitaxel (nab-paclitaxel) and temozolomide with a non-pharmacological intervention known as Specific Mode Electroacupuncture Stimulation (SMES). Albumin-bound paclitaxel is a nanoparticle formulation of paclitaxel that inhibits cell division by stabilizing microtubules, while temozolomide is an alkylating agent that induces DNA damage. The primary challenge in treating high-grade gliomas with paclitaxel is its inability to cross the blood-brain barrier (BBB) due to its high molecular weight. SMES is utilized in this protocol to transiently open the BBB, thereby enhancing the penetration and concentration of albumin-bound paclitaxel within the tumor and surrounding invasive tissues. This integrative approach aims to improve survival outcomes and quality of life for patients with recurrent high-grade gliomas.
- Brand names
- Abraxane
- Other names
- nab-paclitaxel + temozolomide + electroacupunctureSpecific Mode Electroacupuncture Stimulation combined with ABX and TMZ
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on albumin-bound paclitaxel + temozolomide + electroacupuncture.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + temozolomide + electroacupuncture.